This strategic focus on diverse markets positions Proteomics to meet significant healthcare needs and capitalize on the growing demand for effective diagnostic solutions.

With established regulatory pathways and a proprietary Promarker engine for future test development, Proteomics is well-positioned for significant growth in 2025.

Dr. Richard Lipscombe, the managing director, emphasized that this funding will enable the introduction of a comprehensive suite of diagnostic tests.

The annual cost of managing a dialysis patient is approximately $72,000, contributing to an estimated $130 billion annual expense for the US medical industry.

Proteomics International Laboratories has successfully secured $4.5 million in funding to accelerate the launch of its diagnostic tests in the United States and Australia.

The company has established certified testing laboratories in both Australia and the US, and is actively pursuing insurance reimbursement and government listings for its tests.

Proteomics aims to address multiple markets, including the 190 million women affected by endometriosis and up to 20% of Westerners suffering from chronic acid reflux, a significant risk factor for oesophageal cancer.

Globally, 537 million adults live with diabetes, and one in three of these individuals also suffers from chronic kidney disease, which can lead to costly renal failure and dialysis.

The need for Proteomics' testing solutions is underscored by the varying testing requirements for diabetes patients, with low-risk individuals needing only one annual test and high-risk patients requiring quarterly testing.

Each Promarker test is projected to have a gross margin of up to 70%, with initial demand expected to reach between 30,000 and 80,000 tests per year in both Australia and the US.

Proteomics plans to target all GP clinics in Australia, where 96% of surveyed clinics indicated a likelihood of using the PromarkerD test, supported by a patient-driven awareness campaign.

Pricing for the Promarker tests starts at $245 in Australia for PromarkerD and can reach up to $1,500 for more complex tests in the US.